Is the Nanosonics (ASX:NAN) share price in the buy zone?

The Nanosonics Ltd (ASX:NAN) share price has fallen 14% in the last few weeks. Is this a buying opportunity for investors?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nanosonics Ltd (ASX: NAN) share price has been out of form in recent weeks.

Since peaking at $6.87 in late August, the infection control specialist's shares have tumbled 14% lower to $5.89.

Why is the Nanosonics share price down 14% in four weeks?

Investors have been hitting the sell button since the release of its full year results for FY 2020.

However, rather than selling shares because of the pandemic's impact on its performance, I suspect the real driver of this decline was yet another delay with the company's plans to launch new products.

Management warned: "Commercialisation of the new technology is no longer expected to be in FY21 but will likely be in FY22, with the ultimate launch timing continuing to be dependent on the necessary technical milestones being met as well as the timing of individual market regulatory approvals."

This was very disappointing, especially given how many times the company has now failed to deliver on its new product promises.

Is this a buying opportunity?

While Nanosonics certainly isn't a bargain buy, I still believe it could be a good long term investment.

Though, given the tough trading conditions with COVID-19 and the further delay in its new product launches, I wouldn't be expecting too much from its shares over the next 12 months.

Sharing a similar view is Goldman Sachs. This morning its analysts put a neutral rating and $5.50 price target on the company's shares.

It commented: "We believe NAN has successfully transitioned from a disruptive, niche technology provider to a proven leader in its field. However, as a result, there are many facets of execution which this management team must now deliver on to justify the current premium valuation. In particular, we see risk around the timing/impact of new product(s), penetration trajectory, and capital replacement cycle."

The broker also spoke about its premium valuation and the aforementioned product pipeline.

"The stock trades on 72x NTM EV/EBITDA for 26% growth (vs. sector on 22x for 10%). We like the base business for what it is, and, purely on a DCF basis, we believe it is worth A$2.0/sh. As such, current valuation implies the market is allocating A$4.0/sh, i.e. 66% of total, to future product(s) which were first promised in FY17 but have so far shown negligible progress (the latest expectation is FY22)."

"We note that many ASX HC stocks do not stack up well purely on DCF, but we are not aware of any other example in global healthcare where the market has placed such a high value on a pipeline product with so much uncertainty. That is not to say that we believe it is overvalued, we just don't have the data to assess either way, and after many delays, we would advocate prudence," it concluded.

Food for thought.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited. The Motley Fool Australia has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a nervous, but positive, Tuesday for ASX investors.

Read more »

A susccesful person kicks back and relaxes on a comfy chair
Best Shares

If I could only buy and hold a single ASX share forever, it would be this one

There are two reasons why this stock is my first choice...

Read more »

young woman reviewing financial reports at desk with multiple computer screens
Opinions

Brokers' verdict on 4 popular ASX 200 financial stocks

Financials outperformed every other sector in FY25. What should you do now with these 4 stocks?

Read more »

two colleagues high five each other as they sit side by side at a long desk in front of their laptop computers in an office environment.
Share Gainers

Why Bapcor, Ramelius, Sandfire, and WIA Gold shares are rising today

These shares are having a better day than most on Tuesday. But why?

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Share Market News

Is it too late to invest in the record setting S&P 500 stock gains?

A top broker reveals what to expect next from the surging S&P 500 Index.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Boss Energy, DroneShield, Greatland, and Viva Energy shares are tumbling today

Let's see why these shares are out of favour with investors on Tuesday.

Read more »

Man smiling at a laptop because of a rising share price.
Broker Notes

4 ASX shares to buy this week: experts

Looking for investment inspiration?

Read more »

Miner and company person analysing results of a mining company.
Energy Shares

Should you buy Boss Energy shares now after Monday's huge sell-off?

Macquarie gives its verdict on Boss Energy shares following Monday’s crash.

Read more »